Benserazide, a stimulator of prolactin release: A new test in the diagnosis of pituitary prolactin-secreting tumours

A. E. Pontiroli, L. Falsetti, A. M. Voltolini, M. Alberetto, G. Pellicciotta, A. de Pasqua, A. M. Girardi, G. Pozza

Research output: Contribution to journalArticle

Abstract

Benserazide, an extra-cerebral inhibitor of dopa-decarboxylase, elicits prolactin (Prl) release in normal subjects when administered po. The aims of this study were to characterize the effect of benserazide on Prl release and to evaluate benserazide as a diagnostic tool in hyperprolactinaemic patients. In normal subjects, the effect of 50 mg benserazide is reduced to a greater extent by 500 mg than by 200 mg l-dopa, and is nullified by dopamine (DA, 50 mg iv in 180 min), which also decreases fasting plasma Prl levels. Doses of 25, 50 and 150 mg benserazide elicit Prl responses which are slightly and progressively but not significantly higher; a second dose of 50 mg, administered 150 min later, is without effect on Prl release, while TRH (200 μg iv) elicits a further Prl peak. Since it is known that consecutive doses of TRH yield progressively lower Prl responses while 5-hydroxytryptophan (the precursor of serotonin) further increases Prl release in response to benserazide, we hypothesize that, in an area involving both the hypothalamus and the pituitary gland, anti-DA drugs (benserazide), TRH, and serotonin stimulate Prl release by interacting with different kinds of receptors. When administered to hyperprolactinaemic patients, benserazide stimulated Prl release in puerperal women and in patients with functional hyperprolactinaemias, but was totally ineffective in patients with pituitary adenomas, whatever the fasting plasma Prl levels. In 2 patients with a normal sellar tomography in whom benserazide induced no Prl release, a second tomography or computerized axial tomography of the brain, performed respectively 3 and 6 months later, revealed a pituitary microadenoma. These results suggest that benserazide may be a valuable diagnostic tool in the differential diagnosis of hyperprolactinaemia.

Original languageEnglish
Pages (from-to)326-332
Number of pages7
JournalActa Endocrinologica
Volume98
Issue number3
Publication statusPublished - 1981

Fingerprint

Benserazide
Prolactin
Neoplasms
Tomography
Fasting
Serotonin
Dopa Decarboxylase
5-Hydroxytryptophan
Dihydroxyphenylalanine
Hyperprolactinemia
Pituitary Neoplasms
Pituitary Gland
Hypothalamus

ASJC Scopus subject areas

  • Endocrinology

Cite this

Pontiroli, A. E., Falsetti, L., Voltolini, A. M., Alberetto, M., Pellicciotta, G., de Pasqua, A., ... Pozza, G. (1981). Benserazide, a stimulator of prolactin release: A new test in the diagnosis of pituitary prolactin-secreting tumours. Acta Endocrinologica, 98(3), 326-332.

Benserazide, a stimulator of prolactin release : A new test in the diagnosis of pituitary prolactin-secreting tumours. / Pontiroli, A. E.; Falsetti, L.; Voltolini, A. M.; Alberetto, M.; Pellicciotta, G.; de Pasqua, A.; Girardi, A. M.; Pozza, G.

In: Acta Endocrinologica, Vol. 98, No. 3, 1981, p. 326-332.

Research output: Contribution to journalArticle

Pontiroli, AE, Falsetti, L, Voltolini, AM, Alberetto, M, Pellicciotta, G, de Pasqua, A, Girardi, AM & Pozza, G 1981, 'Benserazide, a stimulator of prolactin release: A new test in the diagnosis of pituitary prolactin-secreting tumours', Acta Endocrinologica, vol. 98, no. 3, pp. 326-332.
Pontiroli AE, Falsetti L, Voltolini AM, Alberetto M, Pellicciotta G, de Pasqua A et al. Benserazide, a stimulator of prolactin release: A new test in the diagnosis of pituitary prolactin-secreting tumours. Acta Endocrinologica. 1981;98(3):326-332.
Pontiroli, A. E. ; Falsetti, L. ; Voltolini, A. M. ; Alberetto, M. ; Pellicciotta, G. ; de Pasqua, A. ; Girardi, A. M. ; Pozza, G. / Benserazide, a stimulator of prolactin release : A new test in the diagnosis of pituitary prolactin-secreting tumours. In: Acta Endocrinologica. 1981 ; Vol. 98, No. 3. pp. 326-332.
@article{c57d8fbf42f1416f889d1b9bf00a0d87,
title = "Benserazide, a stimulator of prolactin release: A new test in the diagnosis of pituitary prolactin-secreting tumours",
abstract = "Benserazide, an extra-cerebral inhibitor of dopa-decarboxylase, elicits prolactin (Prl) release in normal subjects when administered po. The aims of this study were to characterize the effect of benserazide on Prl release and to evaluate benserazide as a diagnostic tool in hyperprolactinaemic patients. In normal subjects, the effect of 50 mg benserazide is reduced to a greater extent by 500 mg than by 200 mg l-dopa, and is nullified by dopamine (DA, 50 mg iv in 180 min), which also decreases fasting plasma Prl levels. Doses of 25, 50 and 150 mg benserazide elicit Prl responses which are slightly and progressively but not significantly higher; a second dose of 50 mg, administered 150 min later, is without effect on Prl release, while TRH (200 μg iv) elicits a further Prl peak. Since it is known that consecutive doses of TRH yield progressively lower Prl responses while 5-hydroxytryptophan (the precursor of serotonin) further increases Prl release in response to benserazide, we hypothesize that, in an area involving both the hypothalamus and the pituitary gland, anti-DA drugs (benserazide), TRH, and serotonin stimulate Prl release by interacting with different kinds of receptors. When administered to hyperprolactinaemic patients, benserazide stimulated Prl release in puerperal women and in patients with functional hyperprolactinaemias, but was totally ineffective in patients with pituitary adenomas, whatever the fasting plasma Prl levels. In 2 patients with a normal sellar tomography in whom benserazide induced no Prl release, a second tomography or computerized axial tomography of the brain, performed respectively 3 and 6 months later, revealed a pituitary microadenoma. These results suggest that benserazide may be a valuable diagnostic tool in the differential diagnosis of hyperprolactinaemia.",
author = "Pontiroli, {A. E.} and L. Falsetti and Voltolini, {A. M.} and M. Alberetto and G. Pellicciotta and {de Pasqua}, A. and Girardi, {A. M.} and G. Pozza",
year = "1981",
language = "English",
volume = "98",
pages = "326--332",
journal = "Acta Endocrinologica",
issn = "0001-5598",
publisher = "Munksgaard International Publishers",
number = "3",

}

TY - JOUR

T1 - Benserazide, a stimulator of prolactin release

T2 - A new test in the diagnosis of pituitary prolactin-secreting tumours

AU - Pontiroli, A. E.

AU - Falsetti, L.

AU - Voltolini, A. M.

AU - Alberetto, M.

AU - Pellicciotta, G.

AU - de Pasqua, A.

AU - Girardi, A. M.

AU - Pozza, G.

PY - 1981

Y1 - 1981

N2 - Benserazide, an extra-cerebral inhibitor of dopa-decarboxylase, elicits prolactin (Prl) release in normal subjects when administered po. The aims of this study were to characterize the effect of benserazide on Prl release and to evaluate benserazide as a diagnostic tool in hyperprolactinaemic patients. In normal subjects, the effect of 50 mg benserazide is reduced to a greater extent by 500 mg than by 200 mg l-dopa, and is nullified by dopamine (DA, 50 mg iv in 180 min), which also decreases fasting plasma Prl levels. Doses of 25, 50 and 150 mg benserazide elicit Prl responses which are slightly and progressively but not significantly higher; a second dose of 50 mg, administered 150 min later, is without effect on Prl release, while TRH (200 μg iv) elicits a further Prl peak. Since it is known that consecutive doses of TRH yield progressively lower Prl responses while 5-hydroxytryptophan (the precursor of serotonin) further increases Prl release in response to benserazide, we hypothesize that, in an area involving both the hypothalamus and the pituitary gland, anti-DA drugs (benserazide), TRH, and serotonin stimulate Prl release by interacting with different kinds of receptors. When administered to hyperprolactinaemic patients, benserazide stimulated Prl release in puerperal women and in patients with functional hyperprolactinaemias, but was totally ineffective in patients with pituitary adenomas, whatever the fasting plasma Prl levels. In 2 patients with a normal sellar tomography in whom benserazide induced no Prl release, a second tomography or computerized axial tomography of the brain, performed respectively 3 and 6 months later, revealed a pituitary microadenoma. These results suggest that benserazide may be a valuable diagnostic tool in the differential diagnosis of hyperprolactinaemia.

AB - Benserazide, an extra-cerebral inhibitor of dopa-decarboxylase, elicits prolactin (Prl) release in normal subjects when administered po. The aims of this study were to characterize the effect of benserazide on Prl release and to evaluate benserazide as a diagnostic tool in hyperprolactinaemic patients. In normal subjects, the effect of 50 mg benserazide is reduced to a greater extent by 500 mg than by 200 mg l-dopa, and is nullified by dopamine (DA, 50 mg iv in 180 min), which also decreases fasting plasma Prl levels. Doses of 25, 50 and 150 mg benserazide elicit Prl responses which are slightly and progressively but not significantly higher; a second dose of 50 mg, administered 150 min later, is without effect on Prl release, while TRH (200 μg iv) elicits a further Prl peak. Since it is known that consecutive doses of TRH yield progressively lower Prl responses while 5-hydroxytryptophan (the precursor of serotonin) further increases Prl release in response to benserazide, we hypothesize that, in an area involving both the hypothalamus and the pituitary gland, anti-DA drugs (benserazide), TRH, and serotonin stimulate Prl release by interacting with different kinds of receptors. When administered to hyperprolactinaemic patients, benserazide stimulated Prl release in puerperal women and in patients with functional hyperprolactinaemias, but was totally ineffective in patients with pituitary adenomas, whatever the fasting plasma Prl levels. In 2 patients with a normal sellar tomography in whom benserazide induced no Prl release, a second tomography or computerized axial tomography of the brain, performed respectively 3 and 6 months later, revealed a pituitary microadenoma. These results suggest that benserazide may be a valuable diagnostic tool in the differential diagnosis of hyperprolactinaemia.

UR - http://www.scopus.com/inward/record.url?scp=0019785143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019785143&partnerID=8YFLogxK

M3 - Article

C2 - 7293664

AN - SCOPUS:0019785143

VL - 98

SP - 326

EP - 332

JO - Acta Endocrinologica

JF - Acta Endocrinologica

SN - 0001-5598

IS - 3

ER -